2017年ACC非他汀类药物治疗降低LDL-C管理ASCVD风险专家共识决策路径聚焦更新
该聚焦更新基于FOURIER等试验的最终结果,重点修订了临床ASCVD患者二级预防中依折麦布和PCSK9抑制剂的使用建议,并下调胆汁酸螯合剂的推荐等级,同时新增家族性高胆固醇血症诊断分类信息。
要点
- 临床ASCVD患者在他汀治疗基础上可考虑加用依折麦布或PCSK9抑制剂。
- 胆汁酸螯合剂仅作为依折麦布不耐受患者的可选二级药物。
- 新增基于临床标准(含或不含基因检测)的家族性高胆固醇血症诊断分类。
核心结论
- 基于FOURIER等试验结果,更新了临床ASCVD患者使用依折麦布和PCSK9抑制剂的决策路径。
- 初级预防患者(LDL-C<190 mg/dL伴或不伴糖尿病,或无ASCVD且LDL-C≥190 mg/dL非继发性)的决策路径不变。
- 胆汁酸螯合剂的推荐等级下调,仅作为依折麦布不耐受患者的可选二级药物。
研究设计与样本
- 美国心脏病学会专家共识决策路径写作委员会对2016年版本进行聚焦更新。
- 证据来源包括随机临床试验(如FOURIER、SPIRE-1和-2)及其他已发表资料。
主要发现
- FOURIER试验和SPIRE-1/-2试验公布了临床ASCVD患者及少数高危初级预防患者的心血管结局最终结果。
- 有关急性冠脉综合征后从他汀联合依折麦布治疗中获益的患者类型的新证据已发表。
- 写作委员会认为新数据不足以改变初级预防患者的决策路径和算法。
关键数值与推荐
- 临床ASCVD患者(伴或不伴合并症)接受他汀二级预防时,修订了依折麦布和PCSK9抑制剂的推荐。
- 胆汁酸螯合剂仅推荐作为依折麦布不耐受患者的可选二级药物。
- 新增了基于临床标准(含或不含基因检测)的杂合子和纯合子家族性高胆固醇血症诊断分类信息。
临床怎么用
- 临床ASCVD患者在他汀治疗基础上,可依据更新路径更明确地决策是否加用依折麦布或PCSK9抑制剂。
- 对于初级预防患者,维持2016年共识的决策路径不变。
- 胆汁酸螯合剂不作为首选联合药物,仅考虑用于依折麦布不耐受者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2016, the American College of Cardiology published the first expert consensus decision pathway (ECDP) on the role of non-statin therapies for low-density lipoprotein (LDL)-cholesterol lowering in the management of atherosclerotic cardiovascular disease (ASCVD) risk. Since the publication of that document, additional evidence and perspectives have emerged from randomized clinical trials and other sources, particularly considering the longer-term efficacy and safety of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors in secondary prevention of ASCVD. Most notably, the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial and SPIRE-1 and -2 (Studies of PCSK9 Inhibition and the Reduction of Vascular Events), assessing evolocumab and bococizumab, respectively, have published final results of cardiovascular outcomes trials in patients with clinical ASCVD and in a smaller number of high-risk primary prevention patients. In addition, further evidence on the types of patients most likely to benefit from the use of ezetimibe in addition to statin therapy after acute coronary syndrome has been published. Based on results from these important analyses, the ECDP writing committee judged that it would be desirable to provide a focused update to help guide clinicians more clearly on decision making regarding the use of ezetimibe and PCSK9 inhibitors in patients with clinical ASCVD with or without comorbidities. In the following summary table, changes from the 2016 ECDP to the 2017 ECDP Focused Update are highlighted, and a brief rationale is provided. The content of the full document has been changed accordingly, with more extensive and detailed guidance regarding decision making provided both in the text and in the updated algorithms. Revised recommendations are provided for patients with clinical ASCVD with or without comorbidities on statin therapy for secondary prevention. The ECDP writing committee judged that these new data did not warrant changes to the decision pathways and algorithms regarding the use of ezetimibe or PCSK9 inhibitors in primary prevention patients with LDL-C <190 mg/dL with or without diabetes mellitus or patients without ASCVD and LDL-C ≥190 mg/dL not due to secondary causes. Based on feedback and further deliberation, the ECDP writing committee down-graded recommendations regarding bile acid sequestrant use, recommending bile acid sequestrants only as optional secondary agents for consideration in patients intolerant to ezetimibe. For clarification, the writing committee has also included new information on diagnostic categories of heterozygous and homozygous familial hypercholesterolemia, based on clinical criteria with and without genetic testing. Other changes to the original document were kept to a minimum to provide consistent guidance to clinicians, unless there was a compelling reason or new evidence, in which case justification is provided.
引用
- Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2017. PMID: 28886926. doi:10.1016/j.jacc.2017.07.745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。